nvs

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis buys Advanced Accelerator Applications for $3.9 billion

Novartis AG (NYSE: NVS) has entered into a written agreement with French pharmaceutical company, Advanced Accelerator Applications (NASDAQ: AAAP), for $3.9 billion. Novartis shares were up 0.8 percent and Advanced Accelerator Applications shares wer..

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..